




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 401/14, 417/12, A61K 31/505, 31/44, C07D 413/14 // (C07D 401/14, 211:00, 239:00, 207:00) (C07D 401/14, 207:00, 239:00, 241:00, 211:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 98/11095 (43) International Publication Date: 19 March 1998 (19.03.98)</p>
<p>(21) International Application Number: PCT/GB97/02486 (22) International Filing Date: 12 September 1997 (12.09.97) (30) Priority Data: 9619284.4 16 September 1996 (16.09.96) GB (71) Applicant (for all designated States except US): CELLTECH THERAPEUTICS LIMITED [GB/GB]; 216 Bath Road, Slough, Berkshire SL1 4EN (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): DAVIS, Peter, David [GB/GB]; 10 Astor Park, Ashton Rowant, Oxford OX9 53W (GB). MOFFAT, David, Festus, Charles [GB/GB]; 14 Lonsdale Way, Holyport, Maidenhead, Berkshire SL6 2YX (GB). BATCHELOR, Mark, James [GB/GB]; 13 Delamare Way, Cumnor Hill, Oxford OX2 9HZ (GB). (74) Agent: HALLYBONE, Huw, George; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</p>
<p>(54) Title: SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS</p> <p>(57) Abstract</p> <p>Compounds of general formula (1) are described wherein Het is an optionally substituted heteroaromatic group; R¹ is a hydrogen atom or a straight or branched chain alkyl group; R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group; R³ is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are selective protein kinase inhibitors, particularly the kinases p56^{lck}, ZAP-70 and protein kinase C and are of use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.</p> <div style="text-align: right;">  <p>(1)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUBSTITUTED 2-PYRIMIDINEAMINES, THEIR PREPARATION AND THEIR USE AS PROTEINE KINASE INHIBITORS

5 This invention relates to a series of substituted 2-pyrimidineamines, to processes for their preparation, to pharmaceutical compositions containing them, and to their use in medicine.


10 Protein kinases participate in the signalling events which control the activation, growth and differentiation of cells in response to extracellular mediators and to changes in the environment. In general, these kinases fall into two groups; those which preferentially phosphorylate serine and/or threonine residues and those which preferentially phosphorylate tyrosine residues [Hanks, S K, Hunter T, FASEB. J. 9, 576-596 (1995)]. The serine/threonine kinases include for example, protein kinase C isoforms [Newton A C, J. Biol. Chem. 270, 28495-28498 (1995)] and a group of cyclin-dependent kinases such as cdc2 [Pines J, Trends in Biochemical Sciences 18, 195-197 (1995)]. The tyrosine kinases include membrane-spanning growth factor receptors such as the epidermal growth factor receptor [Iwashita S and Kobayashi M. Cellular Signalling 4, 123-132 (1992)], and cytosolic non-receptor kinases such as p56^{lck} p59^{fyn} ZAP-70 and csk kinases [Chan C *et al* Ann. Rev. Immunol. 12, 555-592 (1994)].

25 Inappropriately high protein kinase activity has been implicated in many diseases resulting from abnormal cellular function. This might arise either directly or indirectly, for example by failure of the proper control mechanisms for the kinase, related for example to mutation, overexpression or inappropriate activation of the enzyme; or by over- or underproduction of cytokines or growth factors also participating in the transduction of signal upstream or downstream of the kinase. In all of these instances, selective inhibition of the action of the kinase might be expected to have a beneficial effect.

35 We have now found a series of substituted 2-pyrimidineamines which are potent and selective inhibitors of protein kinases. The compounds are of

use in the prophylaxis and treatment of immune diseases, hyperproliferative disorders and other diseases in which inappropriate protein kinase action is believed to have a role.

- 5 Thus, according to one aspect of the invention, we provide a compound of formula (1):



- 10 wherein Het is an optionally substituted heteroaromatic group;
R¹ is a hydrogen atom or a straight or branched chain alkyl group;
R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
15 R³ is an optionally substituted aromatic or heteroaromatic group;
and the salts, solvates, hydrates and N-oxides thereof.

In the compounds of formula (1), the group Het may be an optionally substituted C₁₋₁₃ heteroaromatic group, such as a C₁₋₉ heteroaromatic group, containing for example one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms.

In general, Het may be for example a monocyclic heteroaromatic, or a bicyclic or tricyclic fused-ring heteroaromatic group. Monocyclic heteroaromatic groups include for example five- or six-membered heteroaromatic groups containing one, two, three or four heteroatoms selected from oxygen, sulphur or nitrogen atoms. Bicyclic heteroaromatic groups include for example nine- to thirteen-membered fused-ring heteroaromatic groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms. Tricyclic heteroaromatic groups include for example ten- to fourteen-membered fused-ring heteroaromatic

groups containing one, two or more heteroatoms selected from oxygen, sulphur or nitrogen atoms. The heteroaromatic group may be attached to the remainder of the compound of formula (1) through any of its ring carbon atoms.

5

Particular examples of heteroaromatic groups represented by Het include optionally substituted pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, 10 1,3,4-thiadiazole, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, 1,3,5-triazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, benzofuryl, [2,3-dihydro]benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, isobenzothienyl, indolyl, isoindolyl, 3H-indolyl, benzimidazolyl, indazolyl, imidazo[1,2-a]pyridyl, benzothiazolyl, benzoxazolyl, quinoliziny, quinazoliny, phthalaziny, 15 quinoxaliny, cinnoliny, naphthyridiny, pyrido[3,4-b]pyridyl, pyrido[3,2-b]pyridyl, pyrido[4,3-b]pyridyl, quinolyl, isoquinolyl, tetrazolyl, 5,6,7,8-tetrahydroquinolyl, 5,6,7,8-tetrahydroisoquinolyl, purinyl, pteridinyl, carbazolyl, xanthenyl or benzoquinolyl.

Optional substituents which may be present on heteroaromatic groups represented by Het include one, two, three or more substituents, each represented by an atom or group R^4 or $-Alk(R^4)_m$, where R^4 is a halogen atom, or an amino ($-NH_2$), substituted amino, nitro, cyano, hydroxyl ($-OH$), substituted hydroxyl, formyl, carboxyl ($-CO_2H$), esterified carboxyl, thiol 25 ($-SH$), substituted thiol, $-COR^5$ [where R^5 is a $-Alk(R^4)_m$, aryl or heteroaryl group], $-CSR^5$, $-SO_3H$, $-SO_2R^5$, $-SO_2NH_2$, $-SO_2NHR^5$, $SO_2N[R^5]_2$, $-CONH_2$, $-CSNH_2$, $-CONHR^5$, $-CSNHR^5$, $-CON[R^5]_2$, $-CSN[R^5]_2$, $-NHSO_2H$, $-NHSO_2R^5$, $-N[SO_2R^5]_2$, $-NHSO_2NH_2$, $-NHSO_2NHR^5$, $-NHSO_2N[R^5]_2$, $-NHCOR^5$, $-NHCONH_2$, $-NHCONHR^5$, $-NHCON[R^5]_2$, 30 $-NHCSR^5$, $-NHC(O)OR^5$, cycloalkyl, heterocycloalkyl, aryl or heteroaryl group; Alk is a straight or branched C_{1-6} alkylene, C_{2-6} alkenylene or C_{2-6} alkynylene chain, optionally interrupted by one, two or three $-O-$ or $-S-$ atoms or groups selected from $S-(O)-$, $-S(O)_2-$ or $-N(R^6)-$ [where R^6 is a hydrogen atom or a straight or branched chain C_{1-6} alkyl group]; and m is 35 zero or an integer 1, 2 or 3.

When in the group $-\text{Alk}(\text{R}^4)_m$ m is an integer 1, 2 or 3, it is to be understood that the substituent or substituents R^4 may be present on any suitable carbon atom in $-\text{Alk}$. Where more than one R^4 substituent is present these may be the same or different and may be present on the same or different atom in $-\text{Alk}$ or in R^4 as appropriate. Thus for example, $-\text{Alk}(\text{R}^4)_m$ may represent a $-\text{CH}(\text{R}^4)_2$ group, such as a $-\text{CH}(\text{OH})\text{Ar}$ group where Ar is an aryl or heteroaryl group as defined below. Clearly, when m is zero and no substituent R^4 is present the alkylene, alkenylene or alkynylene chain represented by Alk becomes an alkyl, alkenyl or alkynyl group.

When R^4 is a substituted amino group it may be for example a group $-\text{NHR}^5$ [where R^5 is as defined above] or a group $-\text{N}[\text{R}^5]_2$ wherein each R^5 group is the same or different.

When R^4 is a halogen atom it may be for example a fluorine, chlorine, bromine, or iodine atom.

When R^4 is a substituted hydroxyl or substituted thiol group it may be for example a group $-\text{OR}^5$ or $-\text{SR}^5$ respectively.

Esterified carboxyl groups represented by the group R^4 include groups of formula $-\text{CO}_2\text{Alk}^1$ wherein Alk^1 is a straight or branched, optionally substituted C_{1-8} alkyl group such as a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl or t-butyl group; a $\text{C}_{6-12}\text{arylC}_{1-8}\text{alkyl}$ group such as an optionally substituted benzyl, phenylethyl, phenylpropyl, 1-naphthylmethyl or 2-naphthylmethyl group; a $\text{C}_{6-12}\text{aryl}$ group such as an optionally substituted phenyl, 1-naphthyl or 2-naphthyl group; a $\text{C}_{6-12}\text{aryloxyC}_{1-8}\text{alkyl}$ group such as an optionally substituted phenyloxymethyl, phenyloxyethyl, 1-naphthyloxymethyl, or 2-naphthyloxymethyl group; an optionally substituted $\text{C}_{1-8}\text{alkanoyloxyC}_{1-8}\text{alkyl}$ group, such as a pivaloyloxymethyl, propionyloxyethyl or propionyloxypropyl group; or a $\text{C}_{6-12}\text{aroyloxyC}_{1-8}\text{alkyl}$ group such as an optionally substituted benzoyloxyethyl or benzoyloxypropyl group. Optional substituents present on the Alk^1 group include R^4 substituents described above.

When Alk is present in or as a substituent, it may be for example a methylene, ethylene, n-propylene, i-propylene, n-butylene, i-butylene, s-butylene, t-butylene, ethenylene, 2-propenylene, 2-butenylene, 3-butenylene, ethynylene, 2-propynylene, 2-butynylene or 3-butynylene chain, optionally interrupted by one, two, or three -O- or -S-, atoms or -S(O)-, -S(O)₂- or -N(R⁶)- groups.

Cycloalkyl groups represented by the group R⁴ include C₅₋₇ cycloalkyl groups such as cyclopentyl or cyclohexyl groups.

10

Heterocycloalkyl groups represented by the group R⁴ include optionally substituted heteroC₃₋₆cycloalkyl groups containing one or two oxygen, sulphur or nitrogen atoms. Particular examples of such groups include optionally substituted azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperazinyl, morpholinyl or thiomorpholinyl groups. The heterocycloalkyl group may be attached to the remainder of the molecule through any of its ring carbon atoms or, where present, ring nitrogen atom. Optional substituents which may be present on groups of this type include one or two C₁₋₆ alkyl, e.g. methyl or ethyl, hydroxyl (-OH) hydroxyC₁₋₆alkyl, e.g. hydroxymethyl or hydroxyethyl, or C₁₋₆ alkoxy, e.g. methoxy or ethoxy groups. The substituent(s) may be present on any available ring carbon or nitrogen atom as appropriate.

Aryl and heteroaryl groups represented by the groups R⁴, R⁵ or Ar include for example optionally substituted monocyclic or bicyclic C₆₋₁₂ aromatic groups, e.g. phenyl groups, or C₁₋₉ heteroaromatic groups such as those described above in relation to the group Het.

Particularly useful atoms or groups represented by R⁴ or Alk(R⁴)_m as appropriate include fluorine, chlorine, bromine or iodine atoms, or C₁₋₆alkyl, e.g. methyl or ethyl, C₁₋₆ alkylamino, e.g. methylamino or ethylamino, C₁₋₆hydroxyalkyl, e.g. hydroxymethyl or hydroxyethyl, C₁₋₆alkylthiol e.g. methylthiol or ethylthiol, C₁₋₆alkoxy, e.g. methoxy or ethoxy, C₅₋₇cycloalkoxy, e.g. cyclopentyloxy, haloC₁₋₆alkyl, e.g. trifluoromethyl, C₁₋₆alkylamino, e.g. methylamino or ethylamino, amino (-NH₂), aminoC₁₋₆alkyl, e.g. aminomethyl or aminoethyl, C₁₋₆dialkylamino, e.g.

- dimethylamino or diethylamino, imido, such as phthalimido or naphthalimido, e.g. 1,8-naphthalimido, 1,1,3-trioxo-benzo[d]-thiazolidino, nitro, cyano, hydroxyl (-OH), formyl [HC(O)-], carboxyl (-CO₂H), -CO₂Alk¹ [where Alk¹ is as defined above], C₁₋₆ alkanoyl e.g. acetyl, thiol (-SH), thioC₁₋₆alkyl, e.g. thiomethyl or thioethyl, -SC(NH₂)NH₂, sulphonyl (-SO₃H), C₁₋₆alkylsulphonyl, e.g. methyl-sulphonyl, aminosulphonyl (-SO₂NH₂), C₁₋₆alkylaminosulphonyl, e.g. methylaminosulphonyl or ethylaminosulphonyl, C₁₋₆dialkylaminosulphonyl, e.g. dimethylaminosulphonyl or diethylaminosulphonyl, phenylaminosulphonyl, carboxamido (-CONH₂), C₁₋₆alkylaminocarbonyl, e.g. methylaminocarbonyl or ethylaminocarbonyl, C₁₋₆dialkylaminocarbonyl, e.g. dimethylaminocarbonyl or diethylaminocarbonyl, sulphonylamino (-NHSO₂H), C₁₋₆alkylsulphonylamino, e.g. methylsulphonylamino or ethylsulphonylamino, C₁₋₆dialkylsulphonylamino, e.g. dimethylsulphonylamino or diethylsulphonylamino, optionally substituted phenylsulphonylamino, e.g. 2-, 3- or 4- substituted phenylsulphonylamino such as 2-nitrophenylsulphonylamino, aminosulphonylamino (-NHSO₂NH₂), C₁₋₆alkylaminosulphonylamino, e.g. methylaminosulphonylamino or ethylaminosulphonylamino, C₁₋₆dialkylaminosulphonylamino, e.g. dimethylaminosulphonylamino or diethylaminosulphonylamino, phenylaminosulphonylamino, aminocarbonylamino, C₁₋₆alkylaminocarbonylamino e.g. methylaminocarbonylamino or ethylaminocarbonylamino, C₁₋₆dialkylaminocarbonylamino, e.g. dimethylaminocarbonylamino or diethylaminocarbonylamino, phenylaminocarbonylamino, C₁₋₆alkanoylamino, e.g. acetylamino, C₁₋₆alkanoylaminoC₁₋₆alkyl, e.g. acetylaminomethyl, C₁₋₆alkoxycarbonylamino, e.g. methoxycarbonylamino, ethoxycarbonylamino or t-butoxycarbonylamino, or optionally substituted heteroC₃₋₆cycloalkyl, e.g. piperidiny, piperaziny, 3-methyl-1-piperaziny, homopiperaziny or morpholiny groups.
- Where desired, two R⁴ or -Alk(R⁴)_m substituents may be linked together to form a cyclic group such as a cyclic ether, e.g. a C₂₋₆alkylenedioxy group such as ethylenedioxy.
- It will be appreciated that where two or more R⁴ or -Alk(R⁴)_m substituents are present, these need not necessarily be the same atoms and/or groups.

Particular examples of substituents which may be present on the heteroaromatic group Het include one, two or three substituents selected from fluorine, chlorine, bromine or iodine atoms or nitro, cyano, formyl, hydroxyl (-OH), thiol (-SH), amino (-NH₂), -CH₃, -CH₂Hal (where Hal is a fluorine or chlorine atom), -CH(Hal)₂, -C(Hal)₃, -CH₂OH, -CH₂CH₃,
 5 -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -OCH₃, -SCH₃, -NHCH₃, -N(CH₃)₂, -OCH₂OCH₃, -OCH₂SCH₃, -O(CH₂)₂OCH₃, -O(CH₂)₂OCH₂CH₃, -O(CH₂)₂NH₂, -O(CH₂)₂NHCH₃, -O(CH₂)₂N(CH₃)₂, -O(CH₂)₂OH, -CO₂H, -CO₂CH₃, -CO₂CH₂CH₃,
 10 -COCH₃, -CONH₂, -CONHCH₃ or -CON(CH₃)₂ groups.

In the compounds of formula (1), when the group R¹ or the group R⁶ [when present as -N(R⁶)-] is a straight or branched chain alkyl group it may be for example a C₁₋₆ straight or branched chain alkyl group such as
 15 a methyl, ethyl, n-propyl or isopropyl group.

The group R² in compounds according to the invention may be for example a hydrogen or halogen atom such as a fluorine, chlorine, bromine or iodine atom, or a group -X¹-R^{2a} where X¹ is a direct bond or linker atom
 20 or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group.

Linker atoms represented by X¹ when present in compounds of formula (1) include -O- or -S- atoms. When X¹ is a linker group it may be for example a -C(O)-, -C(S)-, -S(O)-, -S(O)₂-, -N(R⁷)- [where R⁷ is a hydrogen atom or a C₁₋₆ alkyl, e.g. methyl or ethyl, group], -CON(R⁷)-, -OC(O)N(R⁷)-, -CSN(R⁷)-, -N(R⁷)CO-, -N(R⁷)C(O)O-, -N(R⁷)CS-, -SON(R⁷), -SO₂N(R⁷), -N(R⁷)SO₂-, -N(R⁷)CON(R⁷)-, -N(R⁷)CSN(R⁷)-, -N(R⁷)SON(R⁷)- or -N(R⁷)SO₂N(R⁷) group.
 25

30 When R^{2a} is present in compounds of the invention it may be for example an optionally substituted straight or branched chain C₁₋₆ alkyl, e.g. C₁₋₃ alkyl, C₂₋₆ alkenyl e.g. C₂₋₄ alkenyl or C₂₋₆ alkynyl e.g. C₂₋₄ alkynyl group. Particular examples of such groups include optionally substituted -CH₃,
 35 -CH₂CH₃, -(CH₂)₂CH₃, -CH(CH₃)₂, -(CH₂)₃CH₃, -CH(CH₃)CH₂CH₃, -CH₂CH(CH₃)₂, -C(CH₃)₃, -(CH₂)₄CH₃, -(CH₂)₅CH₃, -CHCH₂,

-CHCHCH₃, -CH₂CHCH₂, -CHCHCH₂CH₃, -CH₂CHCHCH₃,
-(CH₂)₂CHCH₂, -CCH, -CCCH₃, -CH₂CCH, -CCCH₂CH₃, -CH₂CCCH₃ or
-(CH₂)₂CCH groups. The optional substituents which may be present on
these groups include one, two, three or more substituents selected from
5 halogen atoms, e.g. fluorine, chlorine, bromine or iodine atoms, or
hydroxyl, C₁₋₆ alkoxy, e.g. methoxy or ethoxy, thiol, C₁₋₆ alkylthio, e.g.
methylthio or ethylthio, amino C₁₋₆ alkylamino, e.g. methylamino or
ethylamino, or C₁₋₆ dialkylamino, e.g. dimethylamino or diethylamino
groups.

10

Aromatic groups represented by R³ in compounds of formula (1) include
for example optionally substituted monocyclic or bicyclic fused ring C₆₋₁₂
aromatic groups, such as optionally substituted phenyl, 1- or 2-naphthyl, or
indenyl groups.

15

Heteroaromatic groups represented by R³ include optionally substituted
C₁₋₉ heteroaromatic groups containing for example one, two, three or four
heteroatoms selected from oxygen, sulphur or nitrogen atoms. In general,
the heteroaromatic groups may be for example optionally substituted
20 monocyclic or bicyclic fused ring heteroaromatic groups such as those
generally and particularly described above in relation to the group Het.

In general, when R³ is a heteroaromatic group it is attached to the
remainder of the molecule of formula (1) through any available ring
25 nitrogen atom or, preferably, carbon atom.

Optional substituents which may be present on the aromatic or
heteroaromatic group R³ include one, two, three or more substituents
each represented by the atom or group R⁸ where R⁸ represents an atom
30 or group R⁴ or -Alk(R⁴)_m as defined above in relation to the group Het.
The substituent(s) R⁸ may be attached to any available ring carbon or
nitrogen atom in the group R³. Where two or more R⁸ substituents are
present these need not necessarily be the same atoms and/or groups.

35 Particular R⁸ substituents which may be present on the group R³ in
compounds of formula (1) include those identified above in relation to the

atom or group R^4 or $-Alk(R^4)_m$ and especially include optionally substituted heteroC₃₋₆cycloalkyl groups such as those described above in relation to the group R^4 . Particular examples of such groups include optionally substituted piperazinyl or homopiperazinyl groups, the optional
5 substituents being those discussed previously in relation to hetero-cycloalkyl groups of this type.

The presence of certain substituents in the compounds of formula (1) may enable salts of the compounds to be formed. Suitable salts include
10 pharmaceutically acceptable salts, for example acid addition salts derived from inorganic or organic acids, and salts derived from inorganic and organic bases.

Acid addition salts include hydrochlorides, hydrobromides, hydroiodides,
15 alkylsulphonates, e.g. methanesulphonates, ethanesulphonates, or isethionates, arylsulphonates, e.g. p-toluenesulphonates, besylates or napsylates, phosphates, sulphates, hydrogen sulphates, acetates, trifluoroacetates, propionates, citrates, maleates, fumarates, malonates, succinates, lactates, oxalates, tartrates and benzoates.

20 Salts derived from inorganic or organic bases include alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as magnesium or calcium salts, and organic amine salts such as morpholine, piperidine, dimethylamine or diethylamine salts.

25 Particularly useful salts of compounds according to the invention include pharmaceutically acceptable salts, especially acid addition pharmaceutically acceptable salts.

30 It will be appreciated that depending on the nature of the group Het and the substituents R^2 and R^3 , the compounds of formula (1) may exist as geometrical isomers and/or may have one or more chiral centres so that enantiomers or diastereomers may exist. It is to be understood that the invention extends to all such isomers of the compounds of formula (1), and
35 to mixtures thereof, including racemates.

In one preferred class of compounds of formula (1) R^1 is preferably a hydrogen atom. In these compounds, and in general in compounds of formula (1), R^2 is preferably a hydrogen atom or a group $-X^1-R^{2a}$ where X^1 is as defined for formula (1), and in particular is a direct bond, and R^{2a} is an optionally substituted straight or branched chain C_{1-6} alkyl group, or R^2 is especially a hydrogen atom.

In the compounds according to the invention the heteroaromatic group represented by Het is preferably an optionally substituted five- or six-membered monocyclic heteroaromatic group or a nine- or ten-membered fused-ring heteroaromatic group, each of said groups containing one or two oxygen, sulphur and/or nitrogen atoms. Particularly useful groups of these types include optionally substituted pyridyl, indolyl, benzimidazolyl, indazolyl, benzothiazolyl, quinolyl, isoquinolyl and benzoxazolyl groups. Optionally substituted quinolyl, indazolyl or benzothiazolyl groups are especially useful. The optional substituent(s) may be any of those R^4 or $-Alk(R^4)_m$ atoms or groups generally or particularly described above.

In one general preference, R^3 in compounds of formula (1) is an optionally substituted heteroaromatic group containing one or two oxygen, sulphur and/or nitrogen atoms and is especially a monocyclic heteroaromatic group. Thus in particular R^3 may be an optionally substituted pyridyl group. The pyridyl group may in general be attached to the remainder of the compound of formula (1) through any available ring carbon atom and is in relation to that carbon atom, a 2-, 3- or 4- pyridyl group. Optionally substituted 3-pyridyl groups are especially useful. Optional substituents which may be present on these groups include one, two or three R^8 substituents as described in general and in particular above and hereinafter in the Examples. The R^8 substituent(s) may be attached in particular to any available ring carbon atom in the remainder of the group R^3 .

A particularly useful group of compounds according to the invention has the formula (1) wherein Het is an optionally substituted nine- or ten-membered fused-ring heteroaromatic group containing one or two oxygen, sulphur and/or nitrogen atoms; R^1 and R^2 is each a hydrogen atom and

R³ is an optionally substituted monocyclic heteroaromatic group containing one or two oxygen, sulphur and/or nitrogen atoms.

In compounds of this type, Het is especially an optionally substituted
5 pyridyl, indolyl, benzimidazolyl, benzothiazolyl, quinolyl, isoquinolyl or
benzoxazolyl group. Optionally substituted quinolyl, indazolyl and
benzothiazolyl groups are particularly preferred. The group R³ is
preferably an optionally substituted pyridyl group. The optional
10 substituents which may be present on Het or R³ groups include
respectively those R⁴ or R⁸ substituents generally and particularly
described above in relation to compounds of formula (1).

Particularly useful compounds according to the invention include those
described hereinafter in the Examples and especially include:

15 N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
N-(5-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
N-(6-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
4-(2-(1-Piperazinyl)pyridin-5-yl)-N-(6-quinolyl)-2-pyrimidineamine;
20 N-(2-Methylthiobenzothiazol-6-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-
pyrimidineamine;
and the salts, solvates and hydrates thereof.

Compounds according to the invention are potent and selective inhibitors
25 of protein kinases as demonstrated by differential inhibition of enzymes
such as EGFr kinase, p56^{lck} kinase, ZAP-70 kinase, protein kinase C, Csk
kinase and p59^{fyn} kinase. The ability of the compounds to act in this way
may be simply determined by employing tests such as those described in
the Examples hereinafter.

30 The compounds according to the invention are thus of particular use in the
prophylaxis and treatment of diseases in which inappropriate protein
kinase action plays a role, for example in autoimmune diseases such as
rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus,
35 in transplant rejection, in graft v host disease, in hyperproliferative
disorders such as tumours, psoriasis, in pannus formation in rheumatoid

arthritis, restenosis following angioplasty and atherosclerosis, and in diseases in which cells receive pro-inflammatory signals such as asthma, inflammatory bowel disease and pancreatitis.

- 5 For the prophylaxis or treatment of disease the compounds according to the invention may be administered as pharmaceutical compositions, and according to a further aspect of the invention we provide a pharmaceutical composition which comprises a compound of formula (1) together with one or more pharmaceutically acceptable carriers, excipients or diluents.

10

Pharmaceutical compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical or rectal administration, or a form suitable for administration by inhalation or insufflation.

- 15 For oral administration, the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles and preservatives. The preparations may also contain buffer salts, flavouring, colouring and sweetening agents as appropriate.

30

Preparations for oral administration may be suitably formulated to give controlled release of the active compound.

- 35 For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner.

The compounds for formula (1) may be formulated for parenteral administration by injection e.g. by bolus injection or infusion. Formulations for injection may be presented in unit dosage form, e.g. in glass ampoule
5 or multi dose containers, e.g. glass vials. The compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution
10 with a suitable vehicle, e.g. sterile pyrogen-free water, before use.

In addition to the formulations described above, the compounds of formula (1) may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation or by intramuscular
15 injection.

For nasal administration or administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser,
20 with the use of suitable propellant, e.g. dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.

The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the
25 active ingredient. The pack or dispensing device may be accompanied by instructions for administration.


The quantity of a compound of the invention required for the prophylaxis or
30 treatment of a particular condition will vary depending on the compound chosen, and the condition of the patient to be treated. In general, however, daily dosages may range from around 100ng/kg to 100mg/kg e.g. around 0.01mg/kg to 40mg/kg body weight for oral or buccal administration, from around 10ng/kg to 50mg/kg body weight for
35 parenteral administration and around 0.05mg to around 1000mg e.g.

around 0.5mg to around 1000mg for nasal administration or administration by inhalation or insufflation.

The compounds of the invention may be prepared by a number of processes as generally described below and more specifically in the Examples hereinafter. In the following process description, the symbols Het, R¹-R³, Alk, Alk¹ and Ar when used in the text or formulae depicted are to be understood to represent those groups described above in relation to formula (1) unless otherwise indicated. In the reactions described below, it may be necessary to protect reactive functional groups, for example hydroxy, amino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice [see, for example, Green, T. W. in "Protective Groups in Organic Synthesis", John Wiley and Sons, 1991]. In some instances, deprotection may be the final step in the synthesis of a compound of formula (1) and the processes according to the invention described hereinafter are to be understood to extend to such removal of protecting groups.

20

Thus according to a further aspect of the invention, a compound of formula (1) may be prepared by reaction of a guanidine of formula (2):



25

or a salt thereof

with an enaminone of formula (3):



30

where R⁹ and R¹⁰, which may be the same or different is each a C₁₋₆ alkyl group.

The reaction may be performed in a solvent, for example a protic solvent such as an alcohol, e.g. ethanol, methoxyethanol or propanol, optionally in the presence of a base e.g. an alkali metal base, such as sodium hydroxide or potassium carbonate, at an elevated temperature, e.g. the
5 reflux temperature.

Salts of the compounds of formula (2) include acid salts such as inorganic acid salts e.g. hydrochlorides or nitrates.


10 Intermediate guanidines of formula (2) may be prepared by reaction of the corresponding amine HetNH_2 with cyanamide at an elevated temperature. The reaction may be performed in a solvent such as ethanol at an elevated temperature, e.g. up to the reflux temperature. Where it is desired to obtain a salt of a guanidine of formula (2), the reaction may be
15 performed in the presence of a concentrated acid, e.g. hydrochloric or nitric acid.

The amines HetNH_2 are either known compounds or may be obtained by conventional procedures, for example by hydrogenation of the
20 corresponding nitro derivatives using for example hydrogen in the presence of a metal catalyst in a suitable solvent, for example as more particularly described in the interconversion reactions discussed below. The nitrobenzenes for this particular reaction are either known compounds or may be prepared using similar methods to those used for the
25 preparation of the known compounds.

Intermediate enaminones of formula (3) are either known compounds or may be prepared by reaction of an acetyl derivative $\text{R}^3\text{COCH}_2\text{R}^2$ with an acetal $(\text{R}^9)(\text{R}^{10})\text{NCH}(\text{OCH}_3)_2$ at an elevated temperature. The starting
30 materials for this reaction are either known compounds or may be prepared by methods analogous to those used for the preparation of the known compounds.

In another process according to the invention, a compound of formula (1)
35 may be prepared by displacement of a leaving atom or group in a pyrimidine of formula (4):

16



(4)

[where L is a leaving atom or group], with an amine HetNH₂.

5


The reaction may be performed at an elevated temperature, for example the reflux temperature, where necessary in the presence of a solvent, for example an alcohol, such as 2-ethoxyethanol or isopropanol or a substituted amide such as dimethylformamide, optionally in the presence of a base, for example an organic amine such as pyridine.

10

Particular examples of leaving atoms or groups represented by L in compounds of formula (4) include halogen atoms such as a chlorine or bromine atom, and sulphonyloxy groups, for example alkylsulphonyloxy groups such as a methylsulphonyloxy group.

15

Intermediate pyrimidines of formula (4) may be prepared by cross-coupling a pyrimidine of formula (5):



(5)

20

where Hal is a halogen atom such as a chlorine atom, with an organometallic reagent R³MHal¹, where M is a metal atom, such as a zinc atom, and Hal¹ is a halogen atom, such as a chlorine atom.

25

The reaction may be carried out in the presence of a metal catalyst, for example a metal complex catalyst such as a palladium complex, e.g. tetrakis(triphenylphosphine)palladium, in a solvent such as an ether, e.g. a

cyclic ether such as tetrahydrofuran, at an elevated temperature, e.g. the reflux temperature.

- Organometallic reagents $R^3M\text{Hal}^1$ may be prepared by conventional procedures, for example, where M is a zinc atom, by reaction of a halide $R^3\text{Hal}^2$ where Hal^2 is for example a bromine atom with tert-butyllithium at a low temperature e.g. around -100°C followed by reaction with a zinc salt, e.g. zinc chloride at a low temperature, e.g. around -75°C . Both reactions may be carried out in a solvent such as an ether, e.g. tetrahydrofuran.
- Any reactive groups in R^3 not involved in this or the above-described coupling reaction may need to be in a protected form, the protecting group being removed prior to, during or subsequent to the displacement reaction involving the pyrimidines of formula (4). The starting halides $R^3\text{Hal}^2$ are either known compounds or may be prepared using analogous methods to those used for the preparation of the known compounds.

- Compounds of formula (1) may also be prepared by interconversion of other compounds of formula (1) and it is to be understood that the invention extends to such interconversion processes. Thus, for example, standard substitution approaches employing for example alkylation, arylation, heteroarylation, acylation, thioacylation, sulphonylation, formylation or coupling reactions may be used to add new substituents to and/or extend existing substituents in compounds of formula (1). Alternatively existing substituents in compounds of formula (1) may be modified by for example oxidation, reduction or cleavage reactions to yield other compounds of formula (1).

- The following describes in general terms a number of approaches which can be employed to modify existing Het and/or R^1 or R^3 groups in compounds of formula (1). It will be appreciated that each of these reactions will only be possible where an appropriate functional group exists in a compound of formula (1).

- Thus, for example alkylation, arylation or heteroarylation of a compound of formula (1) may be achieved by reaction of the compound with a reagent AlkL or ArL , where Alk is an alkyl group and Ar is an aryl or heteroaryl

group as defined above in relation to compounds of formula (1) and L is a leaving atom or group as described above.

5 The alkylation or arylation reaction may be carried out in the presence of a base, e.g. an inorganic base such as a carbonate, e.g. caesium or potassium carbonate, an alkoxide, e.g. potassium t-butoxide, or a hydride, e.g. sodium hydride, in a dipolar aprotic solvent such as an amide, e.g. a substituted amide such as dimethylformamide or an ether, e.g. a cyclic ether such as tetrahydrofuran, at around 0°C to around 40°C.

10 In a variation of this process the leaving group L may be alternatively part of the compound of formula (1) and the reaction performed with an appropriate nucleophilic reagent at an elevated temperature. Particular nucleophilic reagents include cyclic amines, such as piperazine,. Where appropriate the reaction may be performed in a solvent such as an alcohol, e.g. ethanol.

20 In another general example of an interconversion process, a compound of formula (1) may be acylated or thioacylated. The reaction may be performed for example with an acyl halide or anhydride in the presence of a base, such as a tertiary amine e.g. triethylamine in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at for example ambient temperature, or by reaction with a thioester in an inert solvent such as tetrahydrofuran at a low temperature such as around 0°C. The reaction is particularly suitable for use with compounds of formula (1) containing

25 primary or secondary amino groups.

In a further general example of an interconversion process, a compound of formula (1) may be formylated, for example by reaction of the compound with a mixed anhydride HCOOCOCH_3 or with a mixture of formic acid and acetic anhydride.

30

Compounds of formula (1) may be prepared in another general interconversion reaction by sulphonylation, for example by reaction of the compound with a reagent $\text{AlkS(O)}_2\text{L}$, or $\text{ArS(O)}_2\text{L}$ in the presence of a base, for example an inorganic base such as sodium hydride in a solvent

35

such as an amide, e.g. a substituted amide such as dimethylformamide at for example ambient temperature. The reaction may in particular be performed with compounds of formula (1) possessing a primary or secondary amino group.

5

In further examples of interconversion reactions according to the invention compounds of formula (1) may be prepared from other compounds of formula (1) by modification of existing functional groups in the latter.

- 10 Thus in one example, ester groups $-\text{CO}_2\text{Alk}^1$ in compounds of formula (1) may be converted to the corresponding acid $[-\text{CO}_2\text{H}]$ by acid- or base-catalysed hydrolysis or by catalytic hydrogenation depending on the nature of the group Alk^1 . Acid- or base-catalysed hydrolysis may be achieved for example by treatment with an organic or inorganic acid, e.g.
- 15 trifluoroacetic acid in an aqueous solvent or a mineral acid such as hydrochloric acid in a solvent such as dioxan or an alkali metal hydroxide, e.g. lithium hydroxide in an aqueous alcohol, e.g. aqueous methanol. Catalytic hydrogenation may be carried out using for example hydrogen in the presence of a metal catalyst, for example palladium on a support such
- 20 as carbon in a solvent such as an ether, e.g. tetrahydrofuran or an alcohol, e.g. methanol.

- In a second example, $-\text{OAlk}^2$ [where Alk^2 represents an alkyl group such as a methyl group] groups in compounds of formula (1) may be cleaved to
- 25 the corresponding alcohol $-\text{OH}$ by reaction with boron tribromide in a solvent such as a halogenated hydrocarbon, e.g. dichloromethane at a low temperature, e.g. around -78°C .

- In another example, alcohol $-\text{OH}$ groups in compounds of formula (1) may
- 30 be converted to a corresponding $-\text{OAlk}$ or $-\text{OAr}$ group by coupling with a reagent AlkOH or ArOH in a solvent such as tetrahydrofuran in the presence of a phosphine, e.g. triphenylphosphine and an activator such as diethyl-, diisopropyl-, or dimethylazodicarboxylate.

- 35 Aminosulphonylamino $[-\text{NHSO}_2\text{NH}_2]$ groups in compounds of formula (1) may be obtained, in another example, by reaction of a corresponding

amine [-NH₂] with sulphamide in the presence of an organic base such as pyridine at an elevated temperature, e.g. the reflux temperature.

- 5 In another example of an interconversion process secondary amine groups in compounds of formula (1) may be alkylated using an alcohol, e.g. ethanol and catalytic hydrogenation, employing for example hydrogen in the presence of a metal catalyst such as palladium on a support such as carbon.
- 10 In a further example, amine [-NH₂] groups in compounds of formula (1) may be obtained by hydrolysis from a corresponding imide by reaction with hydrazine in a solvent such as an alcohol, e.g. ethanol at ambient temperature.
- 15 In another example, a nitro [-NO₂] group may be reduced to an amine [-NH₂], for example by catalytic hydrogenation as just described, or by chemical reduction using for example a metal, e.g. tin or iron, in the presence of an acid such as hydrochloric acid.
- 20 N-oxides of compounds of formula (1) may be prepared for example by oxidation of the corresponding nitrogen base using an oxidising agent such as hydrogen peroxide in the presence of an acid such as acetic acid, at an elevated temperature, for example around 70°C to 80°C, or alternatively by reaction with a peracid such as peracetic acid in a solvent,
- 25 e.g. dichloromethane, at ambient temperature.

Where salts of compounds of formula (1) are desired, these may be prepared by conventional means, for example by reaction of a compound of formula (1) with an appropriate acid or base in a suitable solvent or

30 mixture of solvents, e.g. an organic solvent such as an ether, e.g. diethylether, or an alcohol, e.g. ethanol.

The following Examples illustrate the invention. In the Examples all ¹Hnmr were run at 300MHz unless specified otherwise. All temperatures are in

35 °C.

INTERMEDIATE 1**5-Guanidino-2-methylbenzothiazole nitrate**

5-Amino-2-methylbenzothiazole dihydrochloride (2.50g, 10.54mmol) was partitioned between dichloromethane and saturated aqueous sodium bicarbonate solution. The organic phase was dried (MgSO₄) and evaporated to afford the free base which was dissolved in ethanol (5ml). A solution of cyanamide (660mg, 15.71mmol) in water (1ml) was added followed by concentrated nitric acid (69%, 0.68ml, 10.54mmol) and the resulting mixture was refluxed for 18h. The solid which formed on cooling to room temperature was collected and washed with cold ethanol then diethyl ether to give the title compound (1.36g) as a beige solid m.p. 260-261° (dec.). δ_H (d⁶ DMSO) 2.80 (3H, s), 7.26 (1H, m), 7.37 (4H, s), 7.78 (1H, s), 8.08 (1H, d, \downarrow 8.6Hz) and 9.67 (1H, br s).

INTERMEDIATE 2**5-Guanidinoindole nitrate**

A freshly prepared solution of cyanamide (0.48g, 11.43mmol) in water (1ml) was added to a solution of 5-aminoindole (1.00g, 7.56mmol) in ethanol (5ml). The mixture was treated with concentrated nitric acid (69%, 0.51ml, 7.90mmol) and then refluxed for 18h. A further quantity of cyanamide (0.24g, 5.71mmol) was added and then heating continued for 5h. The reaction mixture was cooled to room temperature and evaporated *in vacuo*. The residue was triturated with ethyl acetate and the resulting precipitate collected and washed with ethyl acetate then diethyl ether to give the title compound (1.67g) as a brown solid m.p. 132-134°. δ_H (d⁶ DMSO) 6.46 (1H, s), 6.92 (1H, dd, \downarrow 1.8, 8.5Hz), 7.07 (4H, s), 7.43 (3H, m), 9.35 (1H, s), and 11.25 (1H, br s).

INTERMEDIATE 3**5-Guanidino-2-methoxypyridine dinitrate**

From 5-amino-2-methoxypyridine (2.43g, 19.60mmol), using the same method as for the preparation of Intermediate 2 to afford the title compound (3.30g) as a dark solid which was used without further purification in the next step. δ_H (d⁶ DMSO) 3.85 (3H, s), 6.88 (1H, d, \downarrow 8.7Hz), 7.33 (4H, s), 7.60 (1H, dd, \downarrow 2.6, 8.7Hz), 8.07 (1H, d, \downarrow 2.6Hz), 8.37 (1H, br s) and 9.37 (1H, s).

INTERMEDIATE 4**5-Bromo-2-(1-piperaziny)pyridine**

A mixture of 2,5-dibromopyridine (10.00g, 42.21mmol) and piperazine (7.98g, 92.79mmol) were heated as a melt at 125° for 3h. On cooling to room temperature the mixture was triturated with 10% methanol-dichloromethane and filtered. The filtrate was evaporated and the residue subjected to column chromatography (silica, 5-8% methanol-dichloromethane) to afford the title compound (7.00g) as a beige solid δ_H (CDCl₃) 2.75 (1H, br s), 2.97 (4H, m), 3.47 (4H, m), 6.52 (1H, d, \downarrow 9.1Hz), 7.52 (1H, dd, \downarrow 9.1, 2.1Hz), and 8.18 (1H, d, \downarrow 2.1Hz).

INTERMEDIATE 5**5-Bromo-2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyridine**

A suspension of Intermediate 4 (7.00g, 28.91mmol) in tetrahydrofuran (60ml) at room temperature was treated with di-*tert*-butyldicarbonate (6.30g, 28.90mmol) and the resulting mixture stirred for 2h, then evaporated and the crude product purified by recrystallisation (ethanol-water) to afford the title compound (8.76g) as a beige solid m.p. 88-90°. δ_H (CDCl₃) 1.47 (9H, s), 3.50 (8H, m), 6.52 (1H, d, \downarrow 9.0Hz), 7.52 (1H, dd, \downarrow 9.0, 2.5Hz) and 8.18 (1H, d, \downarrow 2.5 Hz).

INTERMEDIATE 6**4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-2-chloro-pyrimidine**

A solution of Intermediate 5 (6.00g, 17.50mmol) in anhydrous tetrahydrofuran (150ml) was cooled to -100° (liquid nitrogen-diethyl ether) then treated dropwise with *tert*-butyllithium (22.0ml of a 1.7M solution in pentane, 37.40mmol) and the resulting thick yellow mixture stirred at -100° for 30min. Zinc chloride (35.2ml of a 0.5M solution in tetrahydrofuran, 17.60mmol) was slowly added and the mixture stirred at -75° for 30min then allowed to warm to room temperature whereupon 2,4-dichloropyrimidine (3.98g, 26.71mmol) and tetrakis(triphenylphosphine)-palladium(0) (1.00g, 0.86mmol) were added. The resulting mixture was refluxed for 5h then allowed to cool to room temperature. Saturated aqueous ammonium chloride was added and the mixture was extracted

three times with ethyl acetate. The organic phase was washed with brine then dried (MgSO₄) and evaporated to give the crude product which was purified by recrystallisation (ethyl acetate-hexane) to afford the title compound (3.03g) as a beige solid m.p. 182-183°. δ_H (CDCl₃) 1.48 (9H, s), 3.56 (4H, m), 3.69 (4H, m), 6.68 (1H, d, \downarrow 9.0Hz), 7.49 (1H, d, \downarrow 5.4Hz), 8.24 (1H, dd, \downarrow 2.5, 9.0Hz), 8.49 (1H, d, \downarrow 5.4Hz) and 8.82 (1H, d, \downarrow 2.5Hz).

INTERMEDIATE 7

10 4-(2-(4-Benzoyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-2-chloro-pyrimidine

A solution of 4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-2-chloropyrimidine (8.00g, 21.30mmol) in dichloromethane (60ml) was treated with trifluoroacetic acid and the resulting mixture stirred at room temperature for 2h, then evaporated and reconcentrated four times from dichloromethane. The residue was suspended in a mixture of dichloromethane (150ml) and saturated aqueous sodium bicarbonate (150ml) then treated portionwise with benzyl chloroformate (4.00g, 23.44mmol) in dichloromethane (5ml). The resulting mixture was stirred rapidly for 18h then the organic phase was separated, dried (MgSO₄) and evaporated to give the crude product which was purified by recrystallisation (ethyl acetate-hexane) to afford the title compound (7.85g) as an off-white solid m.p. 145-147°. δ_H (CDCl₃) 3.65-3.77 (8H, m), 5.18 (2H, s), 6.73 (1H, d, \downarrow 9.1Hz), 7.36 (5H, m), 7.52 (1H, d, \downarrow 5.4Hz), 8.31 (1H, dd, \downarrow 2.3, 8.1Hz), 8.54 (1H, d, \downarrow 5.4Hz) and 8.86 (1H, d, \downarrow 2.3Hz).

INTERMEDIATE 8

2-Ethyl-5-nitrobenzoxazole

A solution of 2-amino-4-nitrophenol (2.00g, 12.98mmol) and triethyl orthopropionate (4.57g, 25.95mmol) in anhydrous ethanol (15ml) was treated with p-toluenesulphonic acid (20mg) and the resulting mixture refluxed for 3h. On cooling to room temperature a precipitate formed which was filtered off and dried to afford the title compound (2.11g) as a beige solid m.p. 88-90°. δ_H (CDCl₃) 1.48 (3H, t, \downarrow 7.6Hz), 3.02 (2H, q, \downarrow 7.6Hz), 7.57 (1H, d, \downarrow 9.0Hz), 8.27 (1H, dd, \downarrow 2.3, 9.0Hz) and 8.55 (1H, d, \downarrow 2.3Hz).

INTERMEDIATE 9**5-Amino-2-ethylbenzoxazole**

A solution of Intermediate 8 (1.00g, 5.21 mmol) and ammonium formate (1.64g, 26.04mmol) in ethanol (15ml) was treated with 10% palladium on charcoal (300mg) and the resulting mixture stirred at room temperature for 3h, then filtered through Celite®. The filtrate was evaporated and the residue partitioned between dichloromethane and aqueous sodium bicarbonate. The organic phase was dried (MgSO₄) and evaporated to afford the title compound (0.92g) as a beige solid m.p. 85-87°. δ_H (CDCl₃) 1.42 (3H, t, \downarrow 7.6Hz), 2.91 (2H, q, \downarrow 7.6Hz), 3.50 (2H, br s), 6.70 (1H, dd, \downarrow 2.3, 8.5Hz), 7.02 (1H, d, \downarrow 2.3Hz) and 7.25 (1H, d, \downarrow 8.5Hz).

EXAMPLE 1**4-(2-Chloropyrid-5-yl)-N-(2-methylbenzothiazol-5-yl)-2-pyrimidine-amine**

To a solution of Intermediate 1 (1.00g, 4.20mmol) and 1-(2-chloropyrid-5-yl)-3-dimethylamino-2-propen-1-one (0.88g, 4.18mmol) in propan-2-ol (10ml) was added powdered sodium hydroxide (184mg, 4.60mmol) and the mixture refluxed for 18h. The solid which formed on cooling to room temperature was collected and washed with propan-2-ol then water to afford the title compound (810mg) as a beige solid m.p. 235-237°. δ_H (CDCl₃/CD₃OD, 1:1) 3.31(3H, s), 6.00 (1H, d, \downarrow 5.2Hz), 6.27 (2H, m), 6.34 (1H, dd, \downarrow 2.0, 8.7Hz), 6.51 (1H, d, \downarrow 8.7Hz), 7.20 (2H, m) and 7.78 (1H, d, \downarrow 2.4Hz).

The compounds of Example 2 and 3 were prepared by the same method:

EXAMPLE 2**4-(2-Chloropyrid-5-yl)-N-(5-indolyl)-2-pyrimidineamine**

From Intermediate 2 (1.00g, 4.21mmol) to afford the title compound (795mg) as an ochre solid m.p. 211-214°C. δ_H (d⁶ DMSO) 6.38(1H, s), 7.28-7.39 (4H, m), 7.69 (1H, d, \downarrow 8.4Hz), 7.95 (1H, s), 8.51 (2H, m), 9.14 (1H, d, \downarrow 2.2Hz), 9.48 (1H, s) and 10.93 (1H, br s).

EXAMPLE 3

4-(2-Chloropyrid-5-yl)-N-(2-methoxypyrid-5-yl)-2-pyrimidineamine

From crude Intermediate 3 (1.40g, 4.75mmol) to afford the title compound (1.10g) as a brown solid m.p. 203-205°C. δ_H (d^6 DMSO) 3.83 (3H, s), 6.82 (1H, d, \downarrow 8.9Hz), 7.47 (1H, d, \downarrow 5.2Hz), 7.71 (1H, d, \downarrow 8.3Hz), 8.04 (1H, dd, \downarrow 2.7, 8.9Hz), 8.50 (3H, m), 9.12 (1H, d, \downarrow 2.4Hz) and 9.95 (1H, s).

EXAMPLE 4**N-(2-Methylbenzothiazol-5-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

A mixture of the compound of Example 1 (500mg, 1.41mmol) and piperazine (360mg, 4.24mmol) was heated as a melt at 140° for 2h. On cooling to room temperature the mixture was triturated with dichloromethane and water then filtered and the residue subjected to column chromatography (silica, 5% methanol dichloromethane) to afford the title compound (331mg) as a beige solid m.p. 209-211°. δ_H (d^6 DMSO) 2.78 (7H, m), 3.30 (1H, br s), 3.56 (4H, m), 6.92 (1H, d, \downarrow 9.2Hz), 7.32 (1H, d, \downarrow 5.3Hz), 7.70 (1H, dd, \downarrow 2.0, 8.7Hz), 7.88 (1H, d, \downarrow 8.7Hz), 8.25 (1H, dd, \downarrow 2.5, 9.2Hz), 8.46 (1H, d, \downarrow 5.3), 8.59 (1H, d, \downarrow 1.9Hz), 8.95 (1H, d, \downarrow 2.5Hz) and 9.73 (1H, s).

The compounds of Examples 5 and 6 were prepared by the same method:

EXAMPLE 5**N-(5-Indolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

From the compound of Example 2 (500mg, 1.55mmol) to afford the title compound (217mg) as a pale yellow solid m.p. 245-250° (dec). δ_H (d^6 DMSO) 2.80 (4H, m), 3.38 (1H, br s), 3.50 (4H, m), 6.36 (1H, s), 6.92 (1H, d, \downarrow 9.0), 7.19 (1H, d, \downarrow 5.2Hz), 7.27-7.40 (3H, m), 7.97 (1H, s), 8.24 (1H, d, \downarrow 9.0Hz), 8.36 (1H, d, \downarrow 5.2Hz), 8.90 (1H, s), 9.22 (1H, s) and 10.90 (1H, br s).

EXAMPLE 6**N-(2-Methoxypyrid-5-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidine-amine**

From the compound of Example 3 (500mg, 1.60mmol) to afford the title compound (102mg) as a beige solid m.p. 160-165°. δ_H (d^6 DMSO) 2.80

(4H, m), 3.57 (4H, m), 3.83 (3H, s), 6.81 (1H, d, \downarrow 8.9Hz), 6.93 (1H, d, \downarrow 9.1Hz), 7.28 (1H, d, \downarrow 5.3Hz), 8.04 (1H, d, \downarrow 8.9Hz), 8.21 (1H, d, \downarrow 7.0Hz), 8.40 (1H, d, \downarrow 5.3Hz), 8.58 (1H, s), 8.90 (1H, s) and 9.45 (1H, s).

5

EXAMPLE 7**N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine hydrochloride**

A mixture of 6-aminobenzothiazole (156mg, 1.06mmol) and Intermediate 6 (200mg, 0.53mmol) in 2-ethoxyethanol (3ml) was refluxed for 24h. The solid which formed on cooling to room temperature was collected and washed with 2-ethoxyethanol then diethyl ether to give the title compound (170mg) as a beige solid m.p. 310-312°. δ_H (d^6 DMSO) 3.19 (4H, m), 3.89 (4H, m), 7.08 (1H, d, \downarrow 9.1Hz), 7.40 (1H, d, \downarrow 5.3Hz), 7.83 (1H, dd, \downarrow 2.0, 8.9Hz), 7.99 (1H, d, \downarrow 8.9Hz), 8.35 (1H, dd, \downarrow 2.4, 9.1Hz), 8.51 (1H, d, \downarrow 5.3Hz), 8.72 (1H, d, \downarrow 2.0Hz), 8.98 (1H, d, \downarrow 2.4Hz), 9.19 (1H, s), 9.23 (2H, br s) and 9.88 (1H, s).

The compounds of Examples 8 - 10 were prepared by the same method as the compound of Example 7:

EXAMPLE 8**N-(5-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine hydrochloride**

From 5-aminoindazole (177mg, 1.33mmol) to afford the title compound (173mg) as a beige solid m.p. >300°. δ_H (d^6 DMSO) 3.91 (4H, m), 3.87 (4H, m), 7.06 (1H, d, \downarrow 9.0Hz), 7.30 (1H, d, \downarrow 5.2Hz), 7.47 (1H, d, \downarrow 8.9Hz), 7.62 (1H, d, \downarrow 8.9Hz), 7.99 (1H, s), 8.24 (1H, s), 8.33 (1H, dd, \downarrow 2.3, 9.0Hz), 8.45 (1H, d, \downarrow 5.2Hz), 8.96 (1H, d, \downarrow 2.3Hz), 9.21 (2H, br s), 9.51 (1H, s), and 11.10 (1H, br s).

EXAMPLE 9**N-(6-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine hydrochloride**

From 6-aminoindazole (177mg, 1.33mmol) to afford the title compound (32mg) as a brown solid m.p. 305-310°. δ_H (d^6 DMSO) 3.19 (4H, m), 3.88

(4H, m), 7.07 (1H, d, \underline{J} 8.8Hz), 7.37 (2H, m), 7.61 (1H, d, \underline{J} 8.8Hz), 7.92 (1H, s), 8.31 (1H, s), 8.38 (1H, d, \underline{J} 8.8Hz), 8.51 (1H, d, \underline{J} 5.2Hz), 9.01 (1H, s), 9.15 (2H, br s), 9.73 (1H, s) and 11.16 (1H, br s).

5

EXAMPLE 10**N-(6-Indolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

From 6-aminoindole (141mg, 1.07mmol) to afford after column chromatography (silica, 0.88 ammonia solution-methanol-dichloromethane 10 1:10:89) the title compound (95mg) as a yellow solid m.p. 201-203°. δ_H (d^6 DMSO) 2.78 (4H, t, \underline{J} 4.7Hz), 3.55 (4H, t, \underline{J} 4.7Hz), 6.33 (1H, s), 6.89 (1H, d, \underline{J} 9.1Hz), 7.19-7.27 (3H, m), 7.41 (1H, d, \underline{J} 8.5Hz), 8.10 (1H, s), 8.28 (1H, d, \underline{J} 9.1Hz), 8.39 (1H, d, \underline{J} 5.3Hz), 8.93 (1H, s), 9.37 (1H, s) and 10.96 (1H, s).

15

EXAMPLE 11**N-(2-Methylbenzimidazol-5-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

A solution of 4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-methylbenzimidazol-5-yl)-2-pyrimidineamine (70mg, 0.14mmol) in a mixture of dichloromethane (5ml) and methanol (3ml) was treated with hydrogen chloride (5ml of a 1M solution in diethyl ether, 5.00mmol) then stirred for 18h at room temperature. The precipitate which formed was collected by filtration then subjected to column chromatography (silica, 25 0.88 ammonia solution - methanol - dichloromethane, 1:5:94) to afford the title compound (19mg) as a yellow solid m.p. 245-250°. δ_H (d^6 DMSO) 2.45 (3H, s), 2.80 (4H, m), 3.38 (4H, m), 6.91 (1H, d, \underline{J} 9.0Hz), 7.24 (1H, d, \underline{J} 5.2Hz), 7.35 (2H, s), 8.11 (1H, s), 8.25 (1H, m), 8.39 (1H, d, \underline{J} 5.2Hz), 8.93 (1H, d, \underline{J} 2.2Hz), 9.41 (1H, br s) and 11.50 (1H, br s).

30

The pyrimidineamine starting material for this reaction was prepared by treating a solution of Intermediate 6 (150mg, 0.40mmol) and 5-amino-2-methylbenzimidazole (117mg, 0.80mmol) in propan-2-ol (5ml) with pyridine (0.5ml) then refluxing for 4 days. The mixture was cooled to room temperature then evaporated and the residue subjected to column chromatography (silica, 2-10% methanol-dichloromethane) to afford 4-(2- 35

(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-methylbenzimidazol-5-yl)-2-pyrimidineamine (63mg) as a pale yellow solid m.p. 161-166°. δ_H (CDCl₃/CD₃OD) 1.44 (9H, s), 2.52 (3H, s), 2.98 (2H, br s), 3.51-3.61 (8H, m), 6.68 (1H, d, \downarrow 9.0Hz), 6.97 (1H, d, \downarrow 5.3Hz), 7.19 (1H, d, \downarrow 8.5Hz), 7.42 (1H, d, \downarrow 8.5Hz), 8.07 (1H, s), 8.13 (1H, dd, \downarrow 2.4, 9.0Hz), 8.28 (1H, d, \downarrow 5.3Hz) and 8.89 (1H, d, \downarrow 2.0Hz).

EXAMPLE 12

N-(9-Ethylcarbazol-3-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidine- amine

A solution of 4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(9-ethylcarbazol-3-yl)-2-pyrimidineamine (65mg, 0.12mmol) in dichloromethane (2ml) was treated with trifluoroacetic acid (2ml). After 2h the mixture was evaporated and the residue reconcentrated five times from dichloromethane then three times from diethyl ether. The residue was subjected to column chromatography (silica, 0.88 ammonia solution - methanol - dichloromethane 1:5:94) to afford the title compound (28mg) as a pale yellow solid m.p. 131-137°. δ_H (d⁶DMSO) 1.31 (3H, t, \downarrow 7.1Hz), 2.80 (4H, m), 3.56 (4H, m), 4.42 (2H, q, \downarrow 7.1Hz), 6.93 (1H, d, \downarrow 9.1Hz), 7.17 (1H, m), 7.25 (1H, d, \downarrow 5.3Hz), 7.43 (1H, m), 7.55 (2H, m), 7.76 (1H, dd, \downarrow 2.9, 8.8Hz), 8.03 (1H, d, \downarrow 7.4Hz), 8.27 (1H, dd, \downarrow 2.1, 9.1Hz), 8.41 (1H, d, \downarrow 5.3Hz), 8.57 (1H, d, \downarrow 1.8Hz), 8.95 (1H, d, \downarrow 2.1Hz) and 9.45 (1H, s).

The pyrimidineamine starting material for this reaction was prepared by treating a solution of Intermediate 6 (180mg, 0.48mmol) and 3-amino-9-ethylcarbazole (299mg, 1.44mmol) in anhydrous dimethylformamide (2.5ml) with pyridine (0.1ml) then heating at 110° for 18h. On cooling to room temperature the mixture was partitioned between ethyl acetate and brine, and the organic phase further washed four times with brine, dried (MgSO₄) and evaporated. The residue was subjected to column chromatography (silica, 1% methanol-dichloromethane) to afford 4-(2-(4-*tert*-butoxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(9-ethylcarbazol-3-yl)-2-pyrimidineamine (66mg) as a brown oil. δ_H (CDCl₃) 1.44 (3H, t, \downarrow 7.2Hz), 1.50 (9H, s), 3.56 (4H, m), 3.66 (4H, m), 4.37 (2H, q, \downarrow 7.2Hz), 6.68 (1H, d, \downarrow 9.0Hz), 7.01 (1H, d, \downarrow 5.4Hz), 7.20 (1H, dd, \downarrow 7.0, 7.0Hz), 7.44 (4H, m),

7.67 (1H, dd, \underline{J} 2.1, 8.7 Hz), 8.09 (1H, d, \underline{J} 7.7Hz), 8.24 (1H, dd, \underline{J} 2.5, 9.0Hz), 8.38 (1H, \underline{J} 5.4Hz), 8.40 (1H, d, \underline{J} 2.1Hz) and 8.90 (1H, d, \underline{J} 2.5Hz).

5 **EXAMPLE 13**

N-(5-Benzotriazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine

A solution of N-(5-benzotriazolyl)-4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-2-pyrimidineamine (200mg, 0.39mmol) and ammonium formate (400mg, 6.35mmol) in glacial acetic acid (5ml) was treated with 10% palladium on charcoal (50mg) and stirred for 24h at room temperature. The mixture was filtered through Celite® washing with methanol, then evaporated and the residue subjected to column chromatography (silica, 0.88 ammonia - methanol - dichloromethane, 2:10:88) to afford the title compound (70mg) as a white solid m.p. 280-283°. δ_{H} (d^6 DMSO) 2.79 (4H, m), 3.57 (4H, m), 6.92 (1H, d, \underline{J} 9.1Hz), 7.37 (1H, d, \underline{J} 5.3Hz), 7.59 (1H, d, \underline{J} 9.1Hz), 7.85 (1H, d, \underline{J} 9.1Hz), 8.27 (1H, m), 8.48 (1H, d, \underline{J} 5.3Hz), 8.57 (1H, s), 8.96 (1H, s) and 9.86 (1H, s).

The pyrimidineamine starting material for this reaction was prepared by refluxing a solution of Intermediate 7 (410mg, 1.00mmol) and 5-amino-benzotriazole (147mg, 1.10mol) in 2-ethoxyethanol (5ml) for 4h, then allowing the reaction to cool to room temperature. The mixture was evaporated and the residue subjected to column chromatography (silica, 10% methanol - dichloromethane) to afford N-(5-benzotriazolyl)-4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-2-pyrimidineamine (214mg) as a pale yellow solid m.p. 247-249°. δ_{H} (d^6 DMSO) 3.56 (4H, m), 3.70 (4H, m), 5.12 (2H, s), 6.98 (1H, d, \underline{J} 9.2Hz), 7.35 (6H, m), 7.59 (1H, d, \underline{J} 9.2Hz), 7.86 (1H, d, \underline{J} 9.2Hz), 8.30 (1H, m), 8.51 (1H, d, \underline{J} 5.6Hz), 8.58 (1H, s), 8.99 (1H, s) and 9.86 (1H, s).

The compounds of Examples 14-16 were prepared by the same method as the compound of Example 13. In each case the pyrimidineamine starting material was prepared using the same method used for the pyrimidineamine starting material of the compound of Example 13.

EXAMPLE 14

4-(2-(1-Piperazinyl)pyridin-5-yl)-N-(6-quinolyl)-2-pyrimidineamine

From 4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(6-quinolyl)-2-pyrimidineamine (125mg, 0.24mmol) to afford the title compound (30mg) as a yellow solid m.p. 199-200°. δ_H (d⁶DMSO) 2.78 (4H, m), 3.56 (4H, m), 6.96 (1H, d, \downarrow 9.0Hz), 7.40 (1H, m), 7.41-7.46 (1H, m), 7.94 (1H, d, \downarrow 8.9Hz), 8.03 (1H, d, \downarrow 8.9Hz), 8.21 (1H, d, \downarrow 8.9Hz), 8.30 (1H, d, \downarrow 9.0Hz), 8.51 (1H, m), 8.58 (1H, s), 8.72 (1H, s), 8.96 (1H, s) and 9.93 (1H, s).

4-(2-(4-Benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(6-quinolyl)-2-pyrimidineamine was prepared from 6-aminoquinoline (159mg, 1.10mmol) to afford the title compound a pale beige solid (136mg) m.p. 228-230°. δ_H (CDCl₃) 3.53 (8H, m), 5.01 (2H, s), 6.63 (1H, d, \downarrow 9.0Hz), 6.98 (1H, d, \downarrow 5.3Hz), 7.18-7.28 (7H, m), 7.77 (1H, d, \downarrow 9.1Hz), 7.84 (1H, d, \downarrow 9.1Hz), 8.08 (2H, m), 8.27 (1H, d, \downarrow 5.3Hz), 8.33 (1H, s), 8.52 (1H, d, \downarrow 2.8Hz) and 8.70 (1H, s).

EXAMPLE 15**N-(2-Ethylbenzoxazol-5-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

From 4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-ethylbenzoxazol-5-yl)-2-pyrimidineamine (100mg, 0.19mmol) to afford the title compound (71mg) as a white solid m.p. 156-159°. δ_H (CDCl₃/CD₃OD) 1.40 (3H, t, \downarrow 7.6Hz), 2.93 (6H, m), 3.59 (4H, m), 6.69 (1H, d, \downarrow 8.4Hz), 7.00 (1H, d, \downarrow 5.2Hz), 7.38 (1H, d, \downarrow 8.8Hz), 7.46 (1H, d, \downarrow 8.8Hz), 8.07 (1H, s), 8.17 (1H, d, \downarrow 8.4Hz), 8.29 (1H, d, \downarrow 5.2Hz) and 8.80 (1H, s).

4-(2-(4-Benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-ethylbenzoxazol-5-yl)-2-pyrimidineamine was prepared from Intermediate 9 (111mg, 0.69mmol) to afford a beige solid (248mg). δ_H (CDCl₃) 1.46 (3H, t, \downarrow 7.6Hz), 2.97 (2H, q, \downarrow 7.6Hz), 3.69 (8H, m), 5.18 (2H, s), 6.71 (1H, d, \downarrow 10.0Hz), 7.06 (1H, d, \downarrow 5.5Hz), 7.40 (7H, m), 7.60 (1H, s), 8.12 (1H, s), 8.23 (1H, dd, \downarrow 2.3, 10.0Hz), 8.34 (1H, d, \downarrow 5.5Hz) and 8.88 (1H, d, \downarrow 2.3Hz).

EXAMPLE 16**N-(4-Indolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

From 4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(4-indolyl)-2-pyrimidineamine (74mg, 0.15mmol) to afford the title compound (35mg), as a beige solid m.p. 224-226°. δ_H (d⁶DMSO) 2.77 (4H, m), 3.54 (4H, m), 6.77 (1H, s), 6.89 (1H, d, \underline{J} 9.0Hz), 7.05 (2H, m), 7.26 (2H, m), 7.76 (1H, d, \underline{J} 6.9Hz), 8.23 (1H, d, \underline{J} 9.0Hz), 8.41 (1H, d, \underline{J} 5.3Hz), 8.91 (1H, s), 9.05 (1H, s) and 11.02 (1H, s).

4-(2-(4-Benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(4-indolyl)-2-pyrimidineamine was prepared from 4-aminoindole hydrochloride (99mg, 0.59 mmol) to afford a yellow foam (74mg). δ_H (CDCl₃) 3.65-3.71 (8H, m), 5.19 (2H, s), 6.66 (1H, s), 6.71 (1H, d, \underline{J} 9.0Hz), 7.05 (1H, d, \underline{J} 5.4Hz), 7.14-7.40 (8H, m), 7.67 (1H, br s), 8.05 (1H, d, \underline{J} 7.6Hz), 8.25 (1H, dd, \underline{J} 2.4, 9.0Hz), 8.32 (1H, s), 8.38 (1H, d, \underline{J} 5.4Hz) and 8.93 (1H, d, \underline{J} 2.4Hz).

EXAMPLE 17

N-(2-Ethylbenzoxazol-5-yl)-4-(2-(4-ethylpiperazin-1-yl)pyrid-5-yl)-2-pyrimidineamine

A suspension of 4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-ethylbenzoxazol-5-yl)-2-pyrimidineamine (100mg, 0.19mmol) and 10% palladium on charcoal (30mg) in ethanol (25ml) was stirred under an atmosphere of hydrogen at 50° for 2h, then filtered through Celite® and evaporated. The residue was subjected to column chromatography (silica, 0.88 ammonia solution - methanol - dichloromethane, 1:5:94) to afford the title compound (25mg) as a white solid m.p. 174-176°. δ_H (CDCl₃) 1.15 (3H, t, \underline{J} 7.2Hz), 1.45 (3H, t, \underline{J} 7.6Hz), 2.49 (2H, q, \underline{J} 7.2Hz), 2.58 (4H, m), 2.96 (2H, q, \underline{J} 7.6Hz), 3.71 (4H, m), 6.71 (1H, d, \underline{J} 9.0Hz), 7.04 (1H, d, \underline{J} 5.3Hz), 7.40 (1H, br s), 7.41 (1H, d, \underline{J} 8.7Hz), 7.49 (1H, dd, \underline{J} 2.1, 8.7Hz), 8.09 (1H, d, \underline{J} 2.1Hz), 8.20 (1H, dd, \underline{J} 2.4, 9.0Hz), 8.36 (1H, d, \underline{J} 5.3Hz) and 8.87 (1H, d, \underline{J} 2.1Hz).

EXAMPLE 18

4-(2-(1-Piperazinyl)pyridin-5-yl)-N-(6-quinolyl)-2-pyrimidineamine **N-(2-Methylthiobenzothiazol-6-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

A solution of 4-(2-(4-benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-methylthiobenzothiazol-6-yl)-2-pyrimidineamine (120mg, 0.20mmol) in

glacial acetic acid (10ml) was treated with hydrogen bromide (3ml of 40% aqueous solution) and heated at 55° for 2h. The mixture was evaporated and the residue subjected to column chromatography (silica, 0.88 ammonia solution - methanol - dichloromethane, 1:10:89) to afford the title compound (29mg) as a white solid m.p. 218-220°. δ_H (d⁶DMSO) 2.77 (7H, m), 3.55 (4H, m), 5.73 (1H, s), 6.92 (1H, d, \downarrow 8.8Hz), 7.32 (1H, d, \downarrow 5.3Hz), 7.76 (2H, s), 8.25 (1H, d, \downarrow 8.8Hz), 8.45 (1H, d, \downarrow 5.3Hz), 8.56 (1H, s) and 8.92 (1H, s).

10 The pyrimidineamine starting material for this reaction was prepared using the same method described for the preparation of the starting material of Example 13:

15 4-(2-(4-Benzyloxycarbonylpiperazin-1-yl)pyrid-5-yl)-N-(2-methylthio-benzothiazol-6-yl)-2-pyrimidineamine
was prepared from 6-amino-2-methylthiobenzothiazole (410mg, 1.0mmol) to afford after recrystallisation from ethanol-toluene a white solid (240mg) m.p. 201-202°. δ_H (CDCl₃) 2.78 (3H, s), 3.69 (8H, m), 5.19 (2H, s), 6.71 (1H, d, \downarrow 8.9Hz), 7.06 (1H, d, \downarrow 5.4Hz), 7.28-7.40 (6H, m), 7.45 (1H, d, \downarrow 5.4Hz), 7.79 (1H, d, \downarrow 8.9Hz), 8.19 (1H, d, \downarrow 8.9Hz), 8.42 (2H, m) and 8.91 (1H, s).

EXAMPLE 19

N-(2-Benzimidazolyl)-4-(2-chloropyrid-5-yl)-2-pyrimidineamine

25 A solution of 2-guanidinobenzimidazole (0.83g, 4.75mmol) and 1-(2-chloropyrid-5-yl)-3-dimethylamino-2-propen-1-one (1.00g, 4.75mmol) in propan-2-ol (10ml) was refluxed for 18h. The solid which formed on cooling to room temperature was collected and washed with cold propan-2-ol to afford the title compound (205mg) as a white solid m.p. 308-311°. δ_H (d⁶DMSO) 7.06 (2H, m), 7.45 (2H, m), 7.69 (1H, d, \downarrow 5.3Hz), 7.74 (1H, d, \downarrow 8.4Hz), 8.59 (1H, dd, \downarrow 2.5, 8.4Hz), 8.75 (1H, d, \downarrow 5.2Hz), 9.21 (1H, d, \downarrow 1.9Hz) and 11.30 (1H, br s).

EXAMPLE 20

35 **N-(2-Benzimidazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine**

From N-(2-benzimidazolyl)-4-(2-chloropyrid-5-yl)-2-pyrimidineamine (200mg, 0.62mmol) using the same method used for the preparation of the compound of Example 4 to afford the title compound (108mg) as a beige solid m.p. 285-287°. δ_H (d⁶DMSO) 2.78 (4H, m), 3.60 (4H, m), 6.93 (1H, d, \downarrow 9.1Hz), 7.05 (2H, m), 7.44 (3H, m), 7.49 (1H, d, \downarrow 5.3Hz), 8.28 (1H, dd, \downarrow 2.3, 9.1Hz), 8.55 (1H, d, \downarrow 5.3Hz), 8.96 (1H, d, \downarrow 2.3Hz) and 11.50 (1H, br s).

BIOLOGICAL ACTIVITY

10 The following assays were used to demonstrate the activity and selectivity of compounds according to the invention:

p56^{lck} kinase assay

15 The tyrosine kinase activity of p56^{lck} was determined using a RR-src peptide (RRLIEDNEYTARG) and [γ -³³P]ATP as substrates. Quantitation of the ³³P-phosphorylated peptide formed by the action of p56^{lck} was achieved using an adaption of the method of Geissler *et al* (J. Biol. Chem. (1990) 265, 22255-22261).

20 All assays were performed in 20mM HEPES pH 7.5 containing 10mM MgCl₂, 10mM MnCl₂, 0.05% Brij, 1 μ M ATP (0.5 μ Ci [γ -³³P]ATP) and 0.8mg/ml RR-src. Inhibitors in dimethylsulphoxide (DMSO) were added such that the final concentration of DMSO did not exceed 1%, and enzyme such that the consumption of ATP was less than 10%. After incubation at
25 30°C for 15min, the reaction was terminated by the addition of one-third volume of stop reagent (0.25mM EDTA and 33mM ATP in dH₂O). A 15 μ l aliquot was removed, spotted onto a P-30 filtermat (Wallac, Milton Keynes, UK), and washed sequentially with 1% acetic acid and dH₂O to remove ATP. The bound ³³P-RR-src was quantitated by scintillation counting of
30 the filtermat in a Betaplate scintillation counter (Wallac, Milton Keynes, UK) after addition of Meltilex scintillant (Wallac, Milton Keynes, UK).

The dpm obtained, being directly proportional to the amount of ³³P-RR-src produced by p56^{lck}, were used to determine the IC₅₀ for each compound.
35 The IC₅₀ was defined as the concentration of compound required to reduce the production of ³³P-RR-src by 50%.

In this test, the most active compounds according to the invention have IC₅₀ values of around 1µM and below.

5 **Zap-70 kinase assay**

The tyrosine kinase activity of Zap-70 was determined using a capture assay based on that employed above for p56^{lck}. The RR-src peptide was replaced with polyGlu-Tyr (Sigma; Poole, UK) at a final concentration of 17 µg/ml. After addition of the stopped reaction to the filtermat, trichloroacetic acid 10% (w/v) was employed as the wash reagent instead of acetic acid and a final wash in absolute ethanol was also performed before scintillation counting. IC₅₀ values were determined as described above in the p56^{lck} assay.

15 In this test the most active compounds of the invention have IC₅₀ values of around 500nM and below.

EGFr kinase assay

The tyrosine kinase activity of the EGF receptor (EGFr) was determined using a similar methodology to the p56^{lck} kinase assay, except that the RR-src peptide was replaced by a peptide substrate for EGFr obtained from Amersham International plc (Little Chalfont, UK) and used at the manufacturer's recommended concentration. IC₅₀ values were determined as described previously in the p56^{lck} assay.

25

Protein kinase C assay


Inhibitor activity against protein kinase C (PKC) was determined using PKC obtained from Sigma Chemical Company (Poole, UK) and a commercially available assay system (Amersham International plc, Amersham, UK). Briefly, PKC catalyses the transfer of the γ-phosphate (³²p) of ATP to the threonine group on a peptide specific for PKC. Phosphorylated peptide is bound to phosphocellulose paper and subsequently quantified by scintillation counting. The inhibitor potency is expressed as either (i) the concentration required to inhibit 50% of the enzyme activity (IC₅₀) or (ii) the percentage inhibition achieved by 10µM inhibitor.

35

In this test the most active compounds of the invention have IC₅₀ values of around 1 μ M and below.

CLAIMS

1. A compound of formula (1)




5

(1)

- wherein Het is an optionally substituted heteroaromatic group;
 R¹ is a hydrogen atom or a straight or branched chain alkyl group;
 R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a
 10 direct bond or a linker atom or group, and R^{2a} is an optionally
 substituted straight or branched chain alkyl, alkenyl or alkynyl group;
 R³ is an optionally substituted aromatic or heteroaromatic group;
 and the salts, solvates, hydrates and N-oxides thereof.
- 15 2. A compound according to Claim 1 wherein R¹ is a hydrogen atom
 and R² is a hydrogen atom or a group -X¹-R^{2a} where X¹ is a direct
 bond and R^{2a} is an optionally substituted C₁₋₆alkyl group.
- 20 3. A compound according to Claim 1 or Claim 2 wherein Het is an
 optionally substituted five- or six-membered monocyclic hetero-
 aromatic group or a nine- or ten-membered fused-ring heteroaromatic
 group, each of said groups containing one or two oxygen, sulphur
 and/or nitrogen atoms.
- 25 4. A compound according to Claim 3 wherein Het is an optionally
 substituted pyridyl, indolyl, benzimidazolyl, indazolyl, benzothiazolyl,
 quinolyl, isoquinolyl or benzoxazolyl group.
- 30 5. A compound according to Claim 4 wherein Het is an optionally
 substituted quinolyl, indazolyl or benzothiazolyl group.

6. A compound according to any one of Claims 1 to 5 wherein R³ is an optionally substituted heteroaromatic group containing one or two oxygen, sulphur and/or nitrogen atoms.
- 5 7. A compound according to Claim 6 wherein the heteroaromatic group is a monocyclic heteroaromatic group.
8. A compound according to Claim 7 wherein the monocyclic heteroaromatic group is an optionally substituted pyridyl group.
- 10 9. A compound which is:
 N-(6-Benzothiazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
 N-(5-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
 N-(6-Indazolyl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
 15 4-(2-(1-Piperazinyl)pyridin-5-yl)-N-(6-quinolyl)-2-pyrimidineamine;
 N-(2-Methylthiobenzothiazol-6-yl)-4-(2-(1-piperazinyl)pyrid-5-yl)-2-pyrimidineamine;
 and the salts, solvates and hydrates thereof.
- 20 10. A pharmaceutical composition comprising a compound of formula (1):



(1)

- wherein Het is an optionally substituted heteroaromatic group;
 R¹ is a hydrogen atom or a straight or branched chain alkyl group;
 25 R² is a hydrogen or halogen atom or a group -X¹-R^{2a} where X¹ is a direct bond or a linker atom or group, and R^{2a} is an optionally substituted straight or branched chain alkyl, alkenyl or alkynyl group;
 R³ is an optionally substituted aromatic or heteroaromatic group;
 and the salts, solvates, hydrates and N-oxides thereof; together with
 30 one or more pharmaceutically acceptable carriers, excipients or diluents.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02486

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/14 C07D417/12 A61K31/505 A61K31/44 C07D413/14
 //(C07D401/14,211:00,239:00,207:00),(C07D401/14,207:00,239:00,
 241:00,211:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 588 762 A (CIBA GEIGY AG) 23 March 1994 see the whole document ---	1-10
Y	EP 0 564 409 A (CIBA GEIGY AG) 6 October 1993 see the whole document ---	1-10
Y	WO 95 09851 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 see the whole document ---	1-10
Y	WO 95 09852 A (CIBA GEIGY AG) 13 April 1995 see the whole document ---	1-10
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

18 December 1997

Date of mailing of the international search report

23. 01. 98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 97/02486

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 95 09853 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 see the whole document ---	1-10
Y	WO 95 09847 A (CIBA GEIGY AG ;ZIMMERMANN JUERG (CH)) 13 April 1995 see the whole document ---	1-10
Y	ZIMMERMANN,J. ET AL.: "Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase (PKC) " ARCH.PHARM., vol. 329, no. 7, 1996, WEINHEIM, pages 371-376, XP002050058 see the whole document ---	1-10
Y	ZIMMERMANN,J. ET AL.: "(Phenylamino)pyrimidine (PAP) derivatives: a new class of potent and highly selective PDGF-receptor autophosphorylation inhibitors " BIOORG.&MED.CHEM.LETT., vol. 6, no. 11, 1996, OXFORD, pages 1221-1226, XP002050064 see the whole document ---	1-10
Y	SPADA A P ET AL: "SMALL MOLECULE INHIBITORS OF TYROSINE KINASE ACTIVITY" EXPERT OPINION ON THERAPEUTIC PATENTS, vol. 5, no. 8, 1 January 1995, pages 805-817, XP000567563 see the whole document ---	1-10
Y	PICKETT,W.C. ET AL.: "Modulation of Eicosanoid Biosynthesis by novel Pyridinylpyrimidines" ANN.N.Y.ACAD.SCI., vol. 744, 1994, NEW YORK, pages 299-305, XP002050726 see the whole document ---	1-10
P,Y	WO 97 19065 A (CELLTECH THERAPEUTICS LTD ;DAVIS PETER DAVID (GB); MOFFAT DAVID FE) 29 May 1997 see the whole document ---	1-10
P,Y	ZIMMERMANN,J. ET AL.: "Potent and Selective inhibitors of the ABL-kinase : phenylaminopyrimidine (PAP) derivatives " BIOORG.&MED.CHEM.LETT., vol. 7, no. 2, 1997, OXFORD, pages 187-192, XP002050727 see the whole document -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02486

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0588762 A	23-03-94	JP 6184116 A US 5516775 A	05-07-94 14-05-96
EP 0564409 A	06-10-93	AU 3569493 A CA 2093203 A CN 1077713 A CZ 9300560 A JP 6087834 A MX 9301929 A NZ 247299 A SK 28093 A US 5521184 A ZA 9302397 A	07-10-93 04-10-93 27-10-93 16-02-94 29-03-94 29-07-94 26-07-95 06-04-94 28-05-96 04-10-93
WO 9509851 A	13-04-95	AU 7783394 A CA 2149147 A EP 0672042 A JP 8503970 T	01-05-95 13-04-95 20-09-95 30-04-96
WO 9509852 A	13-04-95	AU 7697594 A CA 2148477 A EP 0672040 A JP 8504834 T US 5521184 A US 5543520 A	01-05-95 13-04-95 20-09-95 28-05-96 28-05-96 06-08-96
WO 9509853 A	13-04-95	AU 7697794 A CA 2148928 A CN 1115982 A CZ 9501722 A EP 0672041 A FI 952607 A HU 72609 A JP 8504215 T NO 952132 A NZ 273617 A PL 309225 A ZA 9407657 A	01-05-95 13-04-95 31-01-96 13-03-96 20-09-95 29-05-95 28-05-96 07-05-96 30-05-95 26-11-96 02-10-95 03-04-95
WO 9509847 A	13-04-95	AU 7697694 A	01-05-95

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 97/02486

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9509847 A		CA 2148931 A EP 0672035 A JP 8503971 T US 5612340 A	13-04-95 20-09-95 30-04-96 18-03-97
WO 9719065 A	29-05-97	AU 7631496 A	11-06-97